pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Oncology · news · pharmadog
← back to Oncology
News · Oncology
1,492
stories
16d
STAT+: Pharmalittle: We’re reading about pharma seeking to protect China deals, a Roche obesity drug, and more
stat
16d
Boehringer Ingelheim bets up to $1B in AI-centered solid tumor collab with Envisagenics
biospace
17d
New federal autism committee head has financial ties to leucovorin
stat
17d
Opinion: The science on relieving cancer symptoms is clear. Why isn’t insurance paying?
stat
17d
Opinion: Social media bans are passing around the world. How will we know if they help teens?
stat
17d
STAT+: Ohio governor’s race is a battle over Covid, health costs, and trust in science
stat
17d
Iambic maintains momentum from string of Big Pharma partnerships by aiming for IPO
fiercebiotech
17d
STAT+: What a vote on Grail’s cancer detection test could mean for the company, patients, and regulators
stat
17d
FDA offers little comment on Grail cancer test ahead of adcomm
endpoints
17d
Boehringer, Envisagenics sign $1B multi-target oncology collaboration
fiercebiotech
17d
STAT+: Lilly’s breast cancer combo wins approval
stat
17d
Telix buys ITM for $1.65B in ‘supercritical’ radiopharma M&A
biospace
18d
President Trump’s newest vaccine ‘demands’ repeat old misinformation
stat
18d
Telix buys ITM in bid to create a ‘radiopharmaceutical powerhouse’
biopharma dive
18d
Cue Biopharma's potential Xolair challenger passes Phase 2 chronic hives trial
endpoints
18d
Behind the outcomes: How whole-patient support is reshaping oncology care
biopharma dive
18d
Opinion: STAT+: The NIH budget should be $100 billion per year
stat
18d
Analysts ‘extremely bullish’ as Telix beams into Novartis’ territory with $1.6B ITM acquisition
fiercebiotech
18d
Retension and Lilly-backed TRex Bio both set out plans to join biotech IPO stampede
fiercebiotech
18d
Citing Replimune approval, experts say localized cancer meds could redefine care
biospace
18d
Mikhail, Davis on board with regulatory framework tailored to rare disease therapies
biospace
18d
Recon: FDA staff raise no major concerns for Grail multi-cancer test ahead of adcomm; Trump admin drafting order to exert contro...
raps
18d
STAT+: Radiopharma companies merge after one receives surprise FDA rejection
stat
19d
Jehovah’s Witnesses allow blood-derived products but keep ban on whole-blood transfusions
stat
20d
FDA approves Lilly's oral SERD combo for second-line breast cancer therapy
endpoints
20d
China plans to transform biotech sector into $522B powerhouse by 2030
biospace
20d
Electra lights up with $350M IPO for pivotal immune-disease drug development
biospace
20d
This week in charts: GSK’s China deals, the $300M IPO club and selling the news
biopharma dive
20d
Artelo’s ex-AstraZeneca cannabinoid agonist holds its own against GLP-1 drug semaglutide in obese mice
fiercebiotech
20d
Ultragenyx prices Sanfilippo gene therapy at $4M; Bristol Myers shelves Orum drug
biopharma dive
← prev
page 7 of 50
next →
